SCHEMBL10245943

SCHEMBL10245943

CCCCNC(=O)c1c[nH]cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
HTT P42858 2/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
HIF1A Q16665 1/20 0.43
HPGD P15428 2/20 0.42
NAAA Q02083 2/20 0.42
KMT2A Q03164 1/20 0.41
ALOX15 P16050 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
CSNK2A2 P19784 1/20 0.40
KDR P35968 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008643 0.95 KDM4E (0.55) KDM4EHTTTSHRSMN1; SMN2LMNA
SCHEMBL3014387 0.94 KDM4E (0.57) KDM4ESMN1; SMN2LMNAHPGDNAAA
SCHEMBL24688715 0.94 KDM4E (0.57) KDM4ESMN1; SMN2LMNAHPGDNAAA
SCHEMBL2995161 0.90 POLB (0.41) KDM4ESMN1; SMN2NPC1RAB9ALMNA
SCHEMBL32662983 0.88 KDM4E (0.45) KDM4ESMN1; SMN2LMNA
SCHEMBL1437230 0.83 CNR1 (0.40) KDM4EHTTSMN1; SMN2HPGDKMT2A
SCHEMBL1437259 0.83 CNR1 (0.41) KDM4EHTTLMNAALOX15L3MBTL1
SCHEMBL22534004 0.83 NPC1 (0.38) KDM4ESMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL390769 0.82 SMN1; SMN2 (0.40) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL27061845 0.81 KDM4E (0.41) KDM4ESMN1; SMN2NPC1RAB9ANAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KDM4E 128/4885HTT 868/4885TSHR 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.